BioArctic is the first company that gained full commercial approval for an Alzheimer disease (modification) treatment (in the US). Together with partner Eisai it will commercialize the large global AD market with approvals pending around the globe. Revenue in 2023 is mainly driven by milestone payments. In 2024 revenue will be driven by patents enrollment at $26.5k/year. With the uncertainty of the roll-out and higher operational costs the earnings for 2023 and 2024 are estimated around break-even. In the coming 12 months continued high volatility can be expected; with buying opportunities (<250kr).